Page 17 - Pharma Industry

Centre rolls out Rs 5,000 crore RLI scheme for pharma, med-tech sectors

Govt rolls out research-linked incentive scheme to boost infra

Lupin receives USFDA approval for generic blood pressure lowering drug

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Metoprolol Succinate extended-release tablets used for lowering blood pressure. The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application is for Metoprolol Succinate extended-release tablets of strengths 25 mg, 50 mg, 100 mg, and 200 mg, Lupin said in a regulatory filing. These are generic equivalent of Toprol-XL Tablets of Sequel Therapeutics, LLC. This product will be manufactured at Lupin's Pithampur facility in India, the company said. Metoprolol Succinate extended-release tablets had an estimated annual sales of USD 305 million in the US, the company said citing IQVIA MAT June 2023 data.

What are generic medicines and how India became the 'pharmacy of the world'

India is the world's largest producer and exporter of generic drugs. But how did it manage to do so? Let us find out here

Defer implementation of NMC regulations: IMA to govt on generic drugs

The Indian Medical Association (IMA) on Monday demanded deferring the implementation of the National Medical Commission regulations that make it mandatory for doctors to prescribe generic drugs, stating the biggest impediment to such medicines is the uncertainty about their quality. The IMA stated that less than 0.1 per cent of the drugs manufactured in India are tested for quality. "This step should be deferred till the government can assure the quality of all the drugs released into the market. Patient care and safety are not negotiable," the association said in a statement. The National Medical Commission (NMC) in its "regulations relating to professional conduct of registered medical practitioners" stated that all doctors must prescribe generic drugs, failing which they will be penalised and even their licence to practise may be suspended for a period. It also asked doctors to avoid prescribing branded generic drugs. Rather than taking the NMC route the government should take

Pharma industry in a huddle after fresh NMC regulations for doctors

"Power thus shifts to chemists instead of doctors. Whichever company offers better incentives, the chemist would prefer it," the industry feared

Medical Council guidelines bar doctors from taking freebies from firms

Industry insiders feel this is a step towards implementing and codifying the Uniform Code of Pharmaceutical Marketing Practices

India has started manufacturing 38 APIs in past 1.5 years: Mandaviya

India has started manufacturing 38 active pharmaceutical ingredients, or APIs, in the last one and a half years on which it was import-dependent, under the production-linked incentive (PLI) scheme for the sector, Union Health Minister Mansukh Mandaviya said here Saturday. Mandaviya said that the 2017 border standoff with China at Doklam triggered India to rethink its self-reliant strategy regarding active pharma components as it was dependent on just one country for the import of 95 per cent of APIs for the formulation industry. The health minister was speaking at the inaugural event of the Healthcare Summit organised at the Indian Institute of Management Ahmedabad (IIMA). Through the PLI scheme, we tried to ensure that the country does not have to import 54 APIs from abroad and our formulation industry gets APIs domestically. I am happy to share that in just a year and a half, India has started manufacturing 38 APIs, which is an example of Atmanirbhar Bharat, he said. The governme

Indian drugs regulators took action against 105 pharma firms, says minister

Indian drugs regulators have taken action against 105 pharmaceutical companies after a risk-based inspection and audit of manufacturing plants, the health minister said on Tuesday

Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak

Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450

Medicines for anxiety, diabetes to get cheaper as NPPA fixes ceiling prices

If drug manufacturers are found flouting the ceiling, they will have to deposit the overcharged amount with the Centre

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Boehringer Ingelheim names Gagandeep Singh as head of India pharma biz

Drug firm Boehringer Ingelheim on Monday said it has appointed Gagandeep Singh as head of the pharma business vertical for the Indian market. The company has appointed Singh as Managing Director and Head of Human Pharma India with effect from July 10. He will also join the Board of Boehringer Ingelheim India, the company said in a statement. Boehringer Ingelheim has three business areas -- Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. "Gagandeep's passion for fostering a customer-focused culture and his experience across complex health ecosystems will be invaluable to the organisation as we continue to strengthen our strategic and sustainability commitment to India," Boehringer Ingelheim Regional Managing Director and Head of Human Pharma for India, Middle East, Turkey and Africa Mohammed Tawil noted. Singh joins Boehringer Ingelheim from AstraZeneca, where he was the Managing Director for India and Africa Cluster Head. He succeeds Vani Manja, who mov

Self-regulatory body for pharma industry on cards: Mansukh Mandaviya

Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants

Regulation largest barrier in pharma, cos should focus on quality: Official

Union Pharma Secretary S Aparna on Thursday said regulations are the biggest barrier to market access in the sector globally, and exhorted local companies to focus on quality. Delivering a video message at the Eighth Global Pharmaceutical Quality Summit, Aparna backed the focus on regulations given the need to have products which are safe and effective. Pharma is highly regulated globally, and regulations contribute the single largest barrier to market access, she said. Indian manufacturing sector has wide-ranging players and the quality culture has to be built across the range, she said. Aparna said Indian industry, which has a very large number of small and medium businesses, is essentially a generic market, and stressed the need to innovate as per changing disease profile and other factors. Indian pharmaceuticals have scale, cost and quality advantages which have enabled companies to make a mark and garner market share in all countries across the world. Cost competitiveness can

A national innovation system for pharma

A world-beating pharmaceutical industry built on innovation is within reach if we make the changes needed in our firms, public research and regulation

NPPA fixes retail prices of 23 drug, including diabetes, blood pressure

National drug pricing regulator NPPA on Friday said it has fixed retail prices of 23 formulations, including the medications to treat diabetes and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has fixed the prices under the Drugs (Price Control) Order, 2013 based on the decision of 113th Authority meeting dated May 26, 2023. As per the notification, the NPPA has fixed the price of one tablet of diabetes drug Gliclazide ER and Metformin Hydrochloride tablets at Rs 10.03. Similarly, the retail price of one tablet of Telmisartan, Chlorthalidone & Cilnidipine tablets at Rs 13.17. The retail price of one tablet of pain reliever medication Trypsin, Bromelain, Rutoside Trihydrate and Diclofenac Sodium tablets has been fixed at Rs 20.51. The NPPA said it has also revised ceiling price of 15 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022). It has also fixed ceiling price of two scheduled formulations. Besides, it has fixed and revise

Corning Inc partners SGD Pharma to set up Rs 500 cr plant in Telangana

SGD Corning Technologies Pvt Ltd, a joint venture between Corning Inc and SGD Pharma will be setting up a glass manufacturing facility in Telangana at an outlay of Rs 500 crore, which will create employment opportunities for 1,500 people directly and indirectly. Telangana Minister for IT and Industries K T Rama Rao in a tweet said, Delighted to break-ground for the world-class glass manufacturing facility of @Corning, a US based fortune 500 company and France based @SGDPharma being established in Vemula, Telangana with an investment of Rs 500 Crore and direct & indirect employment potential of 1500 people. The project will have strategic importance, as it not only supports growth of Telangana's life sciences sector and helps consolidate the state position globally, but also aligned with the efforts of the government, under the leadership of Chief Minister K Chandrasekhar Rao to promote holistic growth, inclusive development and job creation across the State, he said. Meanwhile, an

India a prime example of successfully growing pharma industry: UNICEF

India is a prime example of successfully growing a domestic pharmaceutical industry capable of meeting global supply needs, a top UNICEF official said. India can share its expertise and learnings from the model it used to foster the pharmaceutical industry with countries and regions trying to build capacities including how to incentivise the private sector, ensure regulatory and quality assurance systems in place and develop a globally competitive industry, Tara L Prasad, Senior Manager, Centre for Health Emergency Strategy and Partnerships at UNICEF, said. She is here to attend the third G20 Health Working Group meeting that is being held from June 4 to 6. "Further, India can share lessons on how to create an enabling environment, including investments in human and physical capital, as well as its learnings in moving beyond generic industry to expanding research and development innovator industry," Prasad said. The G20 more broadly can call upon its industry to ensure manufacturer

Govt raises issue of consumers forced to buy entire strip of tablets

Amid complaints about chemists insisting customers on buying entire strip of tablets or capsules, the Centre is making efforts to find some solution to protect the consumer interest and is holding consultations with the pharma industry. The forced buying of a full strip of medicine not only leads to medical wastage but also put unnecessary financial burden on customers. The Department of Consumer Affairs has held the first round of consultation with the senior representatives of pharma and medical devices industry, sources said. In the meeting, the top officials of the Drug Controller General of India were also present. According to sources, the issue was discussed at length in the meeting and the Department suggested them to explore new packing technology for medicines. A suggestion to adopt perforation technology to cut the strip was made to the industry. There was also a recommendation to print manufacturing and expiry date on each strip and even use of QR code, sources added.

Gland Pharma down 33% in two days, Shreyas Shipping hits 20% upper limit

The miss comes on the back of a key customer filing for bankruptcy, high competition from Chinese players, and production shutdowns